2022
Technology and Mental Health: State of the Art for Assessment and Treatment
Harvey PD, Depp CA, Rizzo AA, Strauss GP, Spelber D, Carpenter LL, Kalin NH, Krystal JH, McDonald WM, Nemeroff CB, Rodriguez CI, Widge AS, Torous J. Technology and Mental Health: State of the Art for Assessment and Treatment. American Journal Of Psychiatry 2022, 179: 897-914. PMID: 36200275, DOI: 10.1176/appi.ajp.21121254.Peer-Reviewed Original ResearchConceptsHigh-quality evidenceEcological momentary assessmentTechnology-based interventionsMental health applicationsClinical trialsTreatment strategiesCognitive trainingFunctional capacityDrug AdministrationSystematic reviewVirtual reality approachMomentary assessmentU.S. FoodMental healthFunctional skillsTechnology-based assessmentInterventionTechnology-based approachesTreatmentAssessmentHealth applicationsPhysiological parametersReality approachReviewEmotions
2021
Risks and Benefits of Cannabis and Cannabinoids in Psychiatry
Hill KP, Gold MS, Nemeroff CB, McDonald W, Grzenda A, Widge AS, Rodriguez C, Kraguljac NV, Krystal JH, Carpenter LL. Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. American Journal Of Psychiatry 2021, 179: 98-109. PMID: 34875873, DOI: 10.1176/appi.ajp.2021.21030320.Peer-Reviewed Original ResearchConceptsPsychiatric disordersRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialTherapeutic useEvidence basePlacebo-controlled trialManagement of painBenefits of cannabisSearch of PubMedMental health cliniciansCurrent evidence basePotential side effectsSpecific medical conditionsPsychiatric indicationsFDA indicationClinical trialsHealth cliniciansMedical conditionsReference listsSide effectsChronic cannabisPsychotic disordersDrug AdministrationAdditional articlesMedicinal cannabis
2019
Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial
Abdallah CG, Roache JD, Averill LA, Young-McCaughan S, Martini B, Gueorguieva R, Amoroso T, Southwick SM, Guthmiller K, López-Roca AL, Lautenschlager K, Mintz J, Litz BT, Williamson DE, Keane TM, Peterson AL, Krystal JH, PTSD F. Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemporary Clinical Trials 2019, 81: 11-18. PMID: 30999057, DOI: 10.1016/j.cct.2019.04.009.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderStudy drugClinical trialsTherapeutic effectPharmacotherapy of PTSDFirst placebo-controlled trialPlacebo-controlled clinical trialActive duty military populationDose-related efficacyMedication treatment optionsPlacebo-controlled trialDose-related effectsNovel neural mechanismActive duty militaryKetamine infusionSerotonergic antidepressantsEligible participantsTreatment optionsCase reportNew drug developmentOnly trialSustained reductionVeteran populationDrug AdministrationPilot evidence
2017
Ketamine: A Promising Rapid-Acting Antidepressant
Wilkinson S, Ostroff R, Katz R, Krystal J. Ketamine: A Promising Rapid-Acting Antidepressant. 2017, 223-239. DOI: 10.1007/978-981-10-6577-4_16.Peer-Reviewed Original ResearchMood disordersDeficiency hypothesisInitiation of therapyRapid antidepressant effectsRapid acting antidepressantsEvidence-based treatmentsLong-term riskMood disorders researchRelapse prevention strategiesEfficient therapeutic targetMechanism of actionOral antidepressantsAntidepressant effectsGlutamatergic receptorsGlutamatergic systemNovel antidepressantsSingle doseClinical trialsKetamine exposureRelated symptomsLong-term effectsPsychiatric disordersPrevention strategiesTherapeutic targetDrug AdministrationPosttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology
Kelmendi B, Adams TG, Southwick S, Abdallah CG, Krystal JH. Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology. Clinical Psychology Science And Practice 2017, 24: 281-297. PMID: 31404451, PMCID: PMC6688474, DOI: 10.1111/cpsp.12202.Peer-Reviewed Original Research
2011
Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence
Petrakis IL, Ralevski E, Desai N, Trevisan L, Gueorguieva R, Rounsaville B, Krystal JH. Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence. Neuropsychopharmacology 2011, 37: 996-1004. PMID: 22089316, PMCID: PMC3280636, DOI: 10.1038/npp.2011.283.Peer-Reviewed Original ResearchConceptsPost-traumatic stress disorderSerotonin uptake inhibitorNorepinephrine uptake inhibitorUptake inhibitorAlcohol dependenceMale veteransTreatment of PTSDUse outcomesSymptoms of PTSDDouble-blind conditionsMain outcome measuresEvidence of efficacyComorbid alcohol dependenceCurrent diagnostic criteriaAlcohol use disorderAlcohol use outcomesComorbid conditionsAdjunctive efficacyOutcome measuresOnly FDADiagnostic criteriaUse disordersClinical advantagesAlcohol consumptionDrug Administration
2001
Naltrexone in the Treatment of Alcohol Dependence
Krystal J, Cramer J, Krol W, Kirk G, Rosenheck R. Naltrexone in the Treatment of Alcohol Dependence. New England Journal Of Medicine 2001, 345: 1734-1739. PMID: 11742047, DOI: 10.1056/nejmoa011127.Peer-Reviewed Original ResearchConceptsMonths of placeboSevere alcohol dependenceAlcohol dependencePlacebo-controlled evaluationUse of naltrexoneOpiate receptor antagonistTreatment of menSignificant differencesPercentage of daysStudy medicationNaltrexone groupPlacebo groupNumber of drinksAlcoholics Anonymous meetingsPsychosocial treatmentsNaltrexoneDrug AdministrationPatientsMonthsIndividual counselingNumber of daysPlaceboTreatmentWeeksDays